RxDoctor Payments Data

Lisa Forbess, MD

Adult Congenital Heart Disease · Baltimore, MDNPI 1811952633

Payments from drug & device makers

$1,064in general payments, 2019–2025

Across 21 payments — averaging $50.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$791
  • Johnson & Johnson$48
  • Pfizer$42
  • Novartis$39
  • AstraZeneca$34
  • Philips North America LLC$26
  • plus $85 from 4 others

What the payments were for

  • Travel & lodging$36234%
  • Food & beverage$70266%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult congenital heart disease providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$49,761
Medicare patients
148
Services billed
531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$60,400
EntrestoSacubitril/Valsartan36$57,157
XareltoRivaroxaban20$24,518
FarxigaDapagliflozin Propanediol19$19,092
Repatha SureclickEvolocumab14$17,253
VascepaIcosapent Ethyl11$7,796
Ezetimibe110$2,558
Metoprolol Succinate153$2,503
Atorvastatin Calcium188$2,469
Rosuvastatin Calcium156$2,268
Nebivolol Hcl12$1,081
Valsartan26$967
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide14$758
Amlodipine Besylate95$703
Lisinopril55$535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$42$60,40042 claims
NovartisEntresto$39$57,15736 claims
Johnson & JohnsonXarelto$48$24,51820 claims
AstraZenecaFarxiga$34$19,09219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult congenital heart disease providers in Marylandon file to place this against a meaningful peer group, so we don't.

Other adult congenital heart disease in Baltimore

Where these figures come from

Is this you, or does something look wrong? →